In the same way, we found an increase in CD107a expression for both treatments (20.35 ± 3.04% of CD107a-positive NK cells in CLL PBMCs treated with IL15 and 30.08 ± 4.53% in CLL PBMCs treated with scFvB1IL15 versus 12.42 ± 1.94% for non-treated CLL PBMCs, with p = 0.008 and p = 0.002, respectively). This evidence concerns the gene IL15 and B-cell chronic lymphocytic leukemia.